BIOMARIN PHARMACEUTICAL INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.64 USD | -0.48% |
|
-1.57% | -16.19% |
ETFs positioned on BioMarin Pharmaceutical Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 607 M€ | +0.05% | ||
| 0.03% | 786 M€ | -.--% | ||
| 0.03% | 23 M€ | -.--% | - | |
| 0.03% | 284 M€ | -.--% | ||
| 0.03% | 391 M€ | +8.67% | - | |
| 0.02% | 34 M€ | +8.24% | - | |
| 0.02% | 306 M€ | +5.68% | - | |
| 0.02% | 39 M€ | +5.63% | - | |
| 0.02% | 34 M€ | +3.43% | - | |
| 0.02% | 105 M€ | +3.54% | - | |
| 0.01% | 17 M€ | +2.80% | - | |
| 0.01% | 322 M€ | +13.88% | ||
| 0.01% | 29 M€ | -.--% | - | |
| 0.01% | 6 M€ | +3.89% | ||
| 0.01% | 54 M€ | +0.54% | - | |
| 0.01% | 8 M€ | +0.50% | - | |
| 0.00% | 2 M€ | +3.16% | - | |
| 0.00% | 414 M€ | +11.90% | - | |
| 0.00% | 1,006 M€ | -.--% | ||
| 0.00% | 756 M€ | -0.05% | - |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-15
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
81.03
USD
Average target price
110
USD
Spread / Average Target
+35.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.19% | 15.39B | |
| -2.35% | 89.08B | |
| +2.76% | 40.9B | |
| -13.12% | 32.25B | |
| +54.69% | 25.14B | |
| -8.63% | 11.91B | |
| -42.60% | 11.89B | |
| -12.82% | 11.64B | |
| +7.34% | 9.03B | |
| -7.60% | 8.62B |
- Stock Market
- Equities
- BMRN Stock
- Funds and ETFs BioMarin Pharmaceutical Inc.